All posts are for your entertainment only. Buy and sell at your own risk. In other words, I do my thing - you do your thing.
Followers | 494 |
Posts | 21,867 |
Boards Moderated | 2 |
Alias Born | 02/09/2009 |
Twitter Profile: | Temporarily Unavailable |
Follow on Twitter: | Follow @ Temporarily Unavailable |
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Anybody still here? I've been lurking
This is starting to put in a buy signal
http://stockcharts.com/c-sc/sc?s=RBTI&p=D&b=5&g=0&i=t98092753415&r=3198
what's going on in here?
chart looks hot. where's this contract rumor coming from?
what is the significance of 503?
this dip gets bought.
look at 60min and daily.
I'm calling .15 tomorrow
daddy like
Give me another a new green day on monday and you can say goodbye to the previous high of .06. Is .06 resistance? Doubtful. The increase of volume tells me that that initial move to .06 was an indication pop, signalling a move higher.
It's hard to say where this thing can go given the hype behind the play and the low float, but I would be interested in hopping back in if the next drop is followed by another upward trend.
I bought in at Thursday's close. Chart looks EXCELLENT and I will hold if on Monday we get a close at the high of day.
I'm digging the action. Lets see 23mil volume by the end of the day!
Buy some? no thanks
Doesn't it raise HUGE red flags when the company hasn't had any kind of official update in MANY months?
Looks like I was posting to the wrong board :D
Are operations beginning to revive? I hope all you longs bought more at .01
Form 8-K for STERLING MINING CO
21-Aug-2009
Other Events, Change in Directors or Principal Officers
ITEM 8.01 Other Events
Sterling Mining Company (the "Company") has regained possession of the Sunshine Mine after a ruling from the United States Bankruptcy Court District of Idaho granted Sterling's motion for turnover. The Company took physical possession of the mine site on Wednesday afternoon, August 19, 2009, and began preliminary inspections to ensure the basic infrastructure required for care and maintenance is in good working order. In order to facilitate ongoing security, care and maintenance Sterling has re-hired eleven of the original Sunshine Mine crew. After inspections are complete, Sterling will begin work necessary to resume dewatering. Order of Turnover Motion is attached hereto as Exhibit 99.1
ITEM 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers
Effective August 17, 2009 Robert R. Higdem and Guy Sande were appointed to Sterling's Board of Directors.
Robert Higdem has been with Sterling Mining Company since June 2006 as Environmental Manager and as General Manager since March, 2009. Mr. Higdem has over 8 years experience in the Mining Industry specializing in environmental compliance and environmental quality. He previously worked for the Idaho Department of Environmental Quality for 13 years as an Environmental Compliance Officer, resigning in June 2006 to accept a position with Sterling Mining. Mr. Higdem holds a Bachelor of Science in Environmental Health Science from Boise State University.
Guy Sande has over 22 years production and exploration experience in the mining industry, specializing in mine planning and operations. Before joining Sterling Mining Company in 2006 and becoming Lands Manager in 2007, he previously worked for Coeur d'Alene Mines from 2000 - 2006 in the engineering department and spent four years prior to his tenure at Coeur d'Alene Mines with Golden Queen Mining, bringing the Soledad Mountain project from the exploration stage to final feasibility. In addition, Mr. Sande has extensive experience bringing productivity gains to operations through the creative application of mining, CAD and database software. Mr. Sande attended the Montana College of Mineral Science and Technology, Butte Montana and is a past Chair of the Coeur d'Alene Section of the Society for Mining, Metallurgy and Exploration (SME).
Exhibit No. Description
99.1 Order on Turnover Motion
Form 8-K for STERLING MINING CO
21-Aug-2009
Other Events, Change in Directors or Principal Officers
ITEM 8.01 Other Events
Sterling Mining Company (the "Company") has regained possession of the Sunshine Mine after a ruling from the United States Bankruptcy Court District of Idaho granted Sterling's motion for turnover. The Company took physical possession of the mine site on Wednesday afternoon, August 19, 2009, and began preliminary inspections to ensure the basic infrastructure required for care and maintenance is in good working order. In order to facilitate ongoing security, care and maintenance Sterling has re-hired eleven of the original Sunshine Mine crew. After inspections are complete, Sterling will begin work necessary to resume dewatering. Order of Turnover Motion is attached hereto as Exhibit 99.1
ITEM 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers
Effective August 17, 2009 Robert R. Higdem and Guy Sande were appointed to Sterling's Board of Directors.
Robert Higdem has been with Sterling Mining Company since June 2006 as Environmental Manager and as General Manager since March, 2009. Mr. Higdem has over 8 years experience in the Mining Industry specializing in environmental compliance and environmental quality. He previously worked for the Idaho Department of Environmental Quality for 13 years as an Environmental Compliance Officer, resigning in June 2006 to accept a position with Sterling Mining. Mr. Higdem holds a Bachelor of Science in Environmental Health Science from Boise State University.
Guy Sande has over 22 years production and exploration experience in the mining industry, specializing in mine planning and operations. Before joining Sterling Mining Company in 2006 and becoming Lands Manager in 2007, he previously worked for Coeur d'Alene Mines from 2000 - 2006 in the engineering department and spent four years prior to his tenure at Coeur d'Alene Mines with Golden Queen Mining, bringing the Soledad Mountain project from the exploration stage to final feasibility. In addition, Mr. Sande has extensive experience bringing productivity gains to operations through the creative application of mining, CAD and database software. Mr. Sande attended the Montana College of Mineral Science and Technology, Butte Montana and is a past Chair of the Coeur d'Alene Section of the Society for Mining, Metallurgy and Exploration (SME).
Exhibit No. Description
99.1 Order on Turnover Motion
STRLMQ -- I'm in. Double bottom on a weekly; recently gained possession of the Sunshine Mine - this is a good speculative stock, imo
Chartman, be nice. Kyza - take a loss? You kidding? This is one of the best lotto tickets around. There's no technical indicator you can use to analyze this chart, other than that it's sitting at a bottom. Look at a weekly again. Also, there is a catalyst coming up, which I confirmed in the link I posted regarding the Gendicine patent.
Now if you own too much of it I'd maybe consider taking some off the table, but you're supposed to slowly buy into these things.
At the moment, I have about $400 in it, which is small. If it starts heading towards .10 and gets decent volume, I'll consider adding another $200, and another on a confirmed breakout.
I dont think you'll ever really get a successful pump on this thing without there being a real catalyst. Sure, it's undervalued, but at this point, nobody really cares. I think some news will come out within the next 6months, so I'm going to sit on what I have and buy more at .01, maybe .02. I'm not putting more than $500 in this trade, because 1) I'm smarter than that, and 2)if I slowly accumulate lower, it'll be easy to get out mid range if I need to.
I'll provide you with the liquidity you need ...sell to me at .02.
Gendicine in a patent war
New to me! Apparantly the ruling is expected soon, and if this chart has upside, this may be the catalyst we're needing.
Good luck
http://www.rsc.org/chemistryworld/Issues/2009/October/GeneTherapyInPatentWars.asp
2006 TIMAasia article
http://www.time.com/time/asia/covers/501061030/profiles.html
Groundbreakers
From biotech to nanotech, three Chinese pioneers look to lead the nation to a new scientific frontier
By Hannah Beech | Shenyang
Posted Monday, October 23, 2006; 20:00 HKT
Nowhere is Asia's scientific revolution unfolding more dramatically than in China, where researchers are taking advantage of bounteous funds and pushing hard to fulfill a government mandate to innovate. Here are three Chinese scientists whose discoveries in the emerging biotech and nanotech fields could transform the way we live and help secure China's position as a scientific superpower:
PENG ZHAOHUI
Gene Healing
In 1998, Chinese molecular biologist Peng Zhaohui left the safe confines of San Diego, where he had worked for several years, for a newly built science park in the southern Chinese boomtown of Shenzhen. His immodest goal: to create a gene-therapy medication that would save many lives. Five years and $6.25 million in government seed money later, the firm Peng founded, Shenzhen SiBiono GeneTech Co., became the first corporation in the world to be granted a license for a gene-therapy treatment. Called Gendicine, the drug aims to combat different types of cancer by injecting a virus laced with a tumor-suppressing gene into the human body. By the end of 2005, more than 3,500 Chinese and foreign patients had been treated for 43 types of cancer with the $1,700-per-dose treatment. (A course typically requires at least six doses.) Peng says that combining radiation and chemotherapy with Gendicine is three times more effective than just using the traditional cancer treatments. "Westerners never imagined that the world's first gene-therapy medication would come from China," he says. "But if they had been watching what was happening in China, they might not have been so surprised."
Gendicine's success is due in part to China's relatively relaxed regulatory environment. American biotech firm Introgen, which has developed rival technology to that used by SiBiono, is still awaiting regulatory approval in the U.S. after undergoing exhaustive clinical trials for its gene-therapy drug. Testing can easily take a decade in the U.S., but SiBiono accomplished it in just six years. Moreover, the trials cost SiBiono just $2,500 per patient, compared to around $100,000 per person in America. The possibly looser rules and comparative lack of transparency surrounding Gendicine's approval by the Chinese Food and Drug Administration have prompted criticism that SiBiono may not have adequately tested the long-term effects of its treatment. Peng's efficacy claims have not been internationally verified but he insists that tests have confirmed the drug is safe and effective. Meanwhile, enthusiasm for gene therapy has chilled somewhat in the U.S., after a patient died during clinical trials of another gene-therapy drug in 1999. Still, Peng is hopeful that Gendicine's licensing will help catapult China into the top ranks of this emerging field. Already, the country's gene-therapy guidelines are being used as a model by other nations publishing their own quality-control regulations. "If SiBiono helps China become a leader in biopharma," says Peng, "I will be quite proud."
CHIEN-MIN CHUNG / GETTY IMAGES FOR TIME
CUTTING EDGE: Lu's work extends the life of high-tech metal tools
LU KE
Metal Man
The unprepossessing clump of buildings that make up the government-run Institute of Metal Research in the grim northeastern city of Shenyang hardly looks like the birthplace of groundbreaking science. But inside its dingy halls, Lu Ke, the institute's 41-year-old director, is doing something truly cutting edge. Lu studies metals on a nano scale—one nanometer equals one millionth of a millimeter. Beginning in 2000, he successfully manipulated the atomic structure of copper to create a pliable material that's as strong as steel yet still maintains its original electrical conductivity. Lu's various types of nanometal can add years to the life of high-tech tools and processors. China's largest steel producer, Baosteel, for instance, has affixed a layer of his nanometal to the surface of the rollers it uses to produce steel sheets, thereby greatly extending the tools' longevity.
Just a decade ago, China wasn't a player in nanotech. But in the 1990s, the country unveiled a national science strategy targeting young fields that could be mined for high-profile innovations. The government's $160 million nanotech drive has freed Chinese researchers like Lu from wasting time scrounging for funds. "It's like China's success with Ping-Pong," says Lu, who this year became the first mainland Chinese to be invited to serve as a review editor for the prestigious Washington, D.C.-based Science journal. "When China decides to focus on something, it can achieve success very quickly."
Born in a mountainous village in China's remote west, Lu was one of only three kids from his high school ever to attend college. He later studied in Germany and the U.S., but his sense of obligation led him back to China. Still, he's not yet satisfied with the state of science in his homeland. "We have to give up the existing system based on seniority and reward people with the most talent," he says. "Science requires shaking things up, but people in China are scared of risk." Of course, this call to shake things up comes from a man who has made a life of busting up atoms. "I like disorder," Lu admits. "It's what excites me."
DAVID HARTUNG FOR TIME
THINK SMALL: Shi's tiny ceramic spheres can boost drugs' efficacy
SHI JIANLIN
Targeted Therapy
Sometimes what's in a drug is not as important as what's around it. Orally administered pills typically release one high-concentration jolt that stays in the system for only 10 hours. But a 200-nanometer carrier (equivalent to one-thousandth the width of a human hair) developed last year by Shi Jianlin, a senior researcher at the Institute of Ceramics in Shanghai, may radically change the way we medicate ourselves. Shi, 43, has created microscopic ceramic spheres that can be loaded with drugs and injected into the bloodstream to slowly release over a 50-hour period. Not only do Shi's mini-drug vehicles offer patients a nifty time-release mechanism, they can also target specific parts of the body. The carriers are outfitted with a magnetic particle, so by putting, say, your hand in a magnetic field, the nanovehicles will move directly there and then unload their cache of drugs. Such specific targeting may lower side effects by keeping medication away from parts of the body that adversely react to a drug. "The idea was pretty simple," says Shi. "But getting it to actually work took a lot of work and luck."
So far, Shi's nanocarriers are too costly for mass use, but it isn't his job to bring the price down. That's the domain of a commercial company, and Shi frets that even as the quality of basic research increases in China, the country could lose out because there are not enough domestic firms to convert innovative technology into commercially viable products. Indeed, science may be the one field in which China is still struggling to live up to its reputation as an unsurpassed manufacturer of low-cost goods. For a man who, with the exception of a year's study in Stuttgart, has stayed in China to conduct his research, the disconnect between idea and commercial application is worrisome. "I hope a Chinese firm can do something with our idea," he says. "It would be a pity if we invent something and someone else took advantage of it."
With reporting by Bu Hua/Shanghai
You have this all wrong. The amount of debt left to creditors is apprx $5million.. and yes, this information came directly from the lawyer in charge of the EPIX shell. All it takes is for someone to buy this drug for 25million and the shareholders get paid
5c is good, but go in small enough that you're comfortable sitting on some if you need to. I definitely think something is up
I have to admit to being a .09 buyer, but I went in small enough that I can average down. After reviewing the SEC filings, and know how MMs work, something is definitely cooking
Bidding .05
not if I have 5
Where's this thing headed?
I'm calling .50
I'm more of a stalker of IHUB, but recently decided to go ahead and post. I'm mostly on the yahoo boards making fun of the clowns. I got in BPMA based on the 5minute and couldn't help myself. It's a small position so I can't say I'm too worried about it, but you guys seem pretty certain about its fate :)
Now that some of the smoke has cleared from Friday's news, I think that most people realize that this company is in a form of receivership and it is being managed for the benefit of creditors. But I think many people are confused about what that means, exactly, and what the potential outcomes are, particularly for common shareholders. I wondered the same, so I called Joseph Finn, EPIX's designated assignee overseeing the Assignment. This is what I learned.
One of the most important things I learned, is that the corporate shell has been maintained. There are some reasonable claims against the company, ballparked at $5m. So if the auction on Wednesday were to yield a far greater amount, say $25m (that number is for illustrative purposes only, plucked from the air, that's all), $20m would be left over for the benefit of the company and its shareholders.
So the math here gets interesting. Who bids on Wednesday, and how much is PRX-03140 potentially worth? Well, I am sure the bashers will happily point out that the current Phase II trial includes only one patient. Sure, fine. But this is still a Phase II drug that has been administered to a person with great efficacy. It is a costly proposition to take a drug from pre-clinical development and into Phase 2 trials. Very costly. So what is actually for sale here, the opportunity, is for a well-capitalized company to swoop in and purchase a drug (PRX-03140) for a large market (Alzheimers) at a late stage of development. The early and costly risk is behind them, and there is a possibility they could meet with the FDA and get a Phase III trial approved in short order. I am no doctor, but I do understand business and risk management, and this scenario could play out favorably.
Those are my thoughts, I hope they help. At this point we just don't know what will happen, so it helps to think of all reasonable possibilities.